Phantomics' Emergency Chest-Pain AI Triage Solution 'Angiomics ER' Receives Class 3 Digital Medical Device Approval
Coronary CT-based AI analysis supports triage decisions for emergency chest-pain patients
Phantomics (CEOs Pan Ki Kim and Byoung Wook Choi), a medical AI company, has obtained Class 3 digital medical device manufacturing approval from Korea's Ministry of Food and Drug Safety (MFDS) for Angiomics ER, its coronary CT stenosis diagnostic-support software.
The approval marks the expansion of Phantomics' product portfolio from its cardiac MRI solution Myomics into cardiac CT-based clinical decision support. It is the highest device class in the company's domestic regulatory portfolio and supports rapid care decisions for patients presenting with emergency chest pain.
Key features of Angiomics ER
- Automatic detection of regions with 50% or greater stenosis on coronary CT images using deep-learning algorithms
- Analysis completed within 5 to 10 minutes, shortening time to treatment in the emergency department
- Clinical performance verified in a confirmatory clinical trial at Severance Hospital
- Supports rapid decision-making by clinicians (the final reading remains the responsibility of the physician)
Phantomics plans to expand supply to domestic medical institutions and pursue national health insurance reimbursement listing, while sequentially pursuing overseas regulatory approvals in the United States, Japan and Europe.